Knight Therapeutics Inc. (TSE:GUD) Insider Sells 550,000 Shares

Knight Therapeutics Inc. (TSE:GUD) insider Sime Armoyan sold 550,000 shares of the firm’s stock in a transaction that occurred on Wednesday, March 19th. The shares were sold at an average price of C$6.20, for a total transaction of C$3,410,000.00.

Sime Armoyan also recently made the following trade(s):

• On Monday, March 17th, Sime Armoyan sold 92,200 shares of Knight Therapeutics stock. The shares were sold at an average price of C$6.15, for a total value of C$567,030.00.
• On Thursday, March 13th, Sime Armoyan sold 1,100 shares of Knight Therapeutics stock. The stock was sold at an average price of C$6.10, for a total value of C$6,710.00.
• On Tuesday, March 4th, Sime Armoyan bought 17,600 shares of Knight Therapeutics stock. The stock was purchased at an average price of C$5.48 per share, with a total value of C$96,488.48.

Knight Therapeutics Stock Performance

Shares of Knight Therapeutics stock opened at C$6.18 on Friday. The stock has a market cap of C$625.11 million, a price-to-earnings ratio of -20.63, a P/E/G ratio of -1,013.50 and a beta of 0.50. Knight Therapeutics Inc. has a twelve month low of C$5.09 and a twelve month high of C$6.45. The company’s fifty day moving average is C$5.68 and its 200 day moving average is C$5.58. The company has a quick ratio of 1.79, a current ratio of 3.36 and a debt-to-equity ratio of 7.52.

Wall Street Analysts Forecast Growth

Separately, Research Capitl raised Knight Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, March 11th.

About Knight Therapeutics

Knight Therapeutics Inc develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma.